Movetis obtains EU authorisation for the commercialisation of Resolor (prucalopride)
Movetis announced that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor (prucalopride – a 1mg and 2mg once a day oral tablet) for the symptomatic treatment of chronic constipation (CC) in women in whom laxatives fail to provide adequate relief. Movetis will sell the product itself in certain European markets and expects the first launch in Q1 2010.
Prucalopride is a selective high affinity serotonin (5-HT4) receptor agonist with enterokinetic activity, indicated for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.
The approval by the European Commission means that Resolor is now approved for marketing in the 27 countries of the EU as well as Iceland, Liechtenstein and Norway. As part of its post marketing commitments Movetis has agreed to conduct further clinical studies to investigate the safety and efficacy of prucalopride in the treatment of chronic constipation in males. Furthermore it intends to initiate a clinical program to test the product in children and in opioid-induced constipation.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Protein mingling under blue light
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
Centre Léon Bérard - Lyon, France
Killer silk: Making silk fibers that kill anthrax and other microbes in minutes

Brooks Instrument GmbH - Dresden, Germany
"Allergy cells" can aggravate cancer and psoriasis
Halcygen to acquire wholly owned subsidiary of Hospira
